Skip to main content
    F

    Fate Therapeutics Inc (FATE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.14
    -0.14 (-10.94%)

    Market Cap: $155.74M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -1.62%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.25
    Range-$0.27 - -$0.16
    14 analysts
    Revenue Consensus
    $850.00K
    RangeN/A
    14 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.27
    Range-$0.33 - -$0.23
    5 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.28+5.6%
    60d ago-$0.28+2.9%
    30d ago-$0.28+2.9%
    7d ago-$0.28+2.9%
    Current-$0.27
    Revenue Consensus
    $671.43K
    RangeN/A
    7 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-2737.00%
    ROE-67.80%ROIC-51.32%
    Financial Health
    Debt/Equity0.52xInterest CoverageN/A
    Current Ratio4.41xQuick Ratio4.41x
    Trading Statistics
    Beta2.67Avg Volume1.61M
    52-Week High$3.2352-Week Low$0.95

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 46.4% below its 50-day moving average, and the 50-day average is above the 200-day average. The 14-day RSI is 21.1, below 30, the oversold line.

    Moving Averages

    SMA 10$1.69
    SMA 20$1.89
    SMA 50$2.13
    SMA 200$1.99
    EMA 10$1.59
    EMA 20$1.79
    EMA 50$2.04
    EMA 200$1.99

    MACD

    Line: -0.22Signal: -0.13Hist: -0.08

    ADX

    ADX: 22.6+DI: 10.3-DI: 41.6

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down100.0
    PSAR$1.93

    Bollinger Bands

    Upper Band$2.51
    Lower Band$1.27
    %B Position6553%(Upper)
    Band Width-0.10

    RSI (14-Day)

    Oversold
    21.1

    Momentum Oscillators

    Stoch %K6.1
    Stoch %D6.5
    Williams %R-97.8
    ROC (10d)-43.3%
    Momentum-0.87
    CCI (20d)-217.4
    MFI (14d)27.2

    Volatility Measures

    ATR (14d)$0.17(14.6%)
    StdDev (20d)0.31
    Hist Vol104.9%(High)

    Volume Flow

    VWAP$1.18
    OBV61.9M
    AD Line4.3M
    CMF (20d)-0.258

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio1.3x
    VWMA (20d)$1.79

    Pivot Points

    R3$1.46
    R2$1.39
    R1$1.34
    Pivot Point$1.27
    S1$1.22
    S2$1.15
    S3$1.10

    Advanced Oscillators

    TSI-37.78
    Ultimate Osc30.8
    KST-199.50

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about FATE

    News

    FATE Valuation

    GNG's valuation label for FATE is Overvalued.

    P/B
    1.1x
    All FATE metrics

    FATE Profitability: Margins, ROIC and FCF

    Fate Therapeutics (FATE) has an operating margin of -2737.0% and a net margin of 0.0%. It posts -51.3% ROIC and a -2252.1% FCF margin.

    Operating margin
    -2737.0%
    Net margin
    0.0%
    ROIC
    -51.3%
    ROE
    -67.8%
    FCF margin
    -2252.1%
    FATE financial statements

    Fate Therapeutics Competitors

    The companies most similar to Fate Therapeutics (FATE) include Lineage Cell Therapeutics, Protara Therapeutics and Invivyd.

    Sector: Healthcare

    Companies most similar to Fate Therapeutics

    FATE Analyst Ratings

    Fate Therapeutics (FATE) has a Buy consensus from 11 analysts: 5 Buy or Strong Buy, 6 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    1
    Buy
    4
    Hold
    6
    Sell
    0
    Strong Sell
    0
    FATE stock forecast

    FATE Bull Case vs Bear Case

    Bull case

    • FATE beat EPS estimates in 75.0% of its last 8 reported quarters.

    FATE Earnings: Beat Rate and Next Report

    Fate Therapeutics (FATE) beat the EPS estimate in 6 of the last 8 quarters (75.0%). Its next report is expected on Feb 24, 2027.

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    6.9%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.25
    FATE earnings history

    FATE Earnings Date

    FATE reports Feb 24, 2027. The date is estimated.

    See insider activity

    Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About FATE

    When does FATE report earnings?

    Fate Therapeutics Inc (FATE) is expected to report earnings on Feb 24, 2027.

    Does FATE pay dividends?

    Fate Therapeutics Inc (FATE) does not currently pay a regular dividend.

    What is FATE's market cap?

    Fate Therapeutics Inc (FATE) has a market capitalization of $155.74M with a current stock price of $1.14.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.